Vital Interaction Releases Second Installment of Generational Patient-Communication Study
AUSTIN, Texas, May 8, 2025 /PRNewswire/ -- Vital Interaction, a leading provider of patient-communication technology, today announced the publication of Part 2 of its generational research series: 'Understanding Patient Expectations: Bridging Generational Gaps in Healthcare Communication.' Conducted with The Center for Generational Kinetics (CGK), the latest report uncovers how communication preferences, and frustrations, shift across Gen Z, Millennials, Gen X, and Boomers, spotlighting the practices that build trust, loyalty, and better outcomes.
Key findings include:
Report highlights
'The findings in the study underscore the cornerstone of our mission at Vital Interaction,' said Ben Chapman, CEO. 'By adopting a patient-centered approach, providers can foster trust, improve engagement, and ultimately, deliver better care.'
Availability
'Understanding Patient Expectations: Bridging Generational Gaps in Healthcare Communication' is available for free download at https://guidance.vitalinteraction.com/patient-engagement-study-part-two.
About the Study
Vital Interaction partnered with CGK to survey 1,000 U.S. patients, capturing attitudes across gender, generation, visit type, and frequency. Detailed methodology is included in the white paper.
About Vital Interaction
Vital Interaction is an award-winning leader in patient-communication technology, trusted by over 13,000 providers to send 40 million personalized messages annually. Its Smart List Engine leverages appointment, clinical, and billing data to automate highly targeted outreach that improves engagement, retention, and outcomes. Learn more at vitalinteraction.com.
About The Center for Generational Kinetics
CGK is the premier research firm focused on Gen Z, Millennials, Gen X, and Baby Boomers. Its PhD-led team delivers original quantitative and qualitative insights that help organizations drive measurable results across generations.
Contact:
Craig Hollis
Director of Demand Generation
Vital Interaction
512-487-7625
[email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/vital-interaction-releases-second-installment-of-generational-patient-communication-study-302450023.html
SOURCE Vital Interaction
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Vogue
2 hours ago
- Vogue
How a Temporary Break From Alcohol Eased My Anxiety
For decades, drinking alcohol has been synonymous with socializing, celebrating, and relaxing. But these days, the youth seems to be rewriting the narrative—or at least taking a more conscientious approach. According to The New York Times, alcohol consumption among Gen Z has plummeted compared to Millennials when they were the same age. According to another report, 28% of Gen Z in the United States say they never drink alcohol, compared to only 16% of Millennials. I wanted to understand why so many of my peers were taking the sober path. Is it because we've grown up in an era where 'wellness' is a lifestyle—an era in which green juices, adaptogens and matcha lattes are as trendy as some clothing brands? Or, is it that our health consciousness has combined with our notorious predisposition for anxiety has naturally led to a boycott on booze? To find out, I decided to give sobriety a two month trial for myself. Spoiler: Since my experiment, I have gone back to drinking alcohol from time to time. Still, I truly believe that the experiment changed me for the better. It helped me understand how alcohol impacts me in every way, from my emotions to my physical health. It also helped me be more mindful of my reasons for wanting a drink and better at knowing when I might be attempting to use alcohol as an emotional crutch. Most importantly, it helped me get a handle on my anxiety—something I always thought was out of my control. How the body responds to quitting alcohol When you quit alcohol, your body starts a recovery process that can be noticed within the first 24 hours. The liver, which is primarily responsible for metabolizing alcohol, begins to detoxify, which reduces liver inflammation and improves its functions. In the first few days, blood sugar levels also stabilize, as alcohol interferes with glucose regulation. After one or two weeks, improvements in sleep quality and skin hydration are common. Studies have shown that long term abstinence from alcohol reduces the risk of cardiovascular disease, strengthens the immune system, and improves the balance of the intestinal microbiota.
Associated Press
13 hours ago
- Associated Press
DermRays Celebrates 13 Years of Skincare Innovation with Exclusive Anniversary Sale and Groundbreaking 1450nm Laser Device for 2026
PLEASANTON, Calif., Aug. 15, 2025 /PRNewswire/ -- DermRays, a pioneer in at-home skincare technology, marks its 13th anniversary with a celebration of its best-selling devices and a sneak peek at its upcoming 1450nm laser skincare tool, slated for launch in early 2026. This milestone underscores the brands commitment to merging cutting-edge science with accessible beauty solutions. Anniversary Spotlight: Award-Winning Skincare Heroes To thank customers for their trust, DermRays is offering limited-time discounts on three transformative devices designed to rejuvenate skin at home: 1. DermRays Revive The first and only at-home laser with ultra-high energy for collagen regeneration. Ideal for reducing fine lines and boosting collagen, its a clinic-grade tool for a fraction of the cost. Revive uses cutting-edge 1064nm laser technology, the same as that employed by leading salon brands. 2. FusionGlow Multi-Functional Microcurrent Toning Device Beyond Microcurrent: 5 Skincare Technologies You Need. Comprehensive Skin Revitalization: Brighten, Hydrate, Rejuvenate. Achieve radiant, firm skin in 14 days with clinically visible results backed by SGS. 3. LED Light Therapy Silicone Mask Your daily skincare companion: blue, red, infrared, and mixed light for every need. Only 15 minutes a day for youthful and radiant skin. 'For 13 years, we've empowered users to take control of their skincare routines with safe, effective technology,' says Dr. Yang Lin, Brand Director at DermRays. 'Our anniversary sale is a tribute to our community-and just the beginning of whats next.' 4. The Future: 1450nm Laser Skincare Device DermRays is set to revolutionize at-home treatments again with its 1450nm laser device (expected Q1 2026). It stimulates natural collagen production to smooth fine lines, restore firmness, and reverse signs of aging. This tool will expand the brands professional-grade offerings, bridging the gap between spa treatments and home care. Join the Celebration From August 1-31, 2025, enjoy exclusive anniversary bundles and discounts on DermRays bestselling devices. Follow @DermRays on social media for giveaways and live demos. About DermRays Since 2011, DermRays has combined dermatological research with accessible technology, offering FDA/CE/UKCA-cleared, non-invasive devices for radiant, youthful skin at home. View original content to download multimedia: SOURCE DermRays
Yahoo
a day ago
- Yahoo
Epigenetics Market worth US$4.29 billion in 2030 with 13.9% CAGR
DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Epigenetics Market, valued at US$2.03 billion in 2024, stood at US$2.24 billion in 2025 and is projected to advance at a resilient CAGR of 13.9% from 2025 to 2030, culminating in a forecasted valuation of US$4.29 billion by the end of the period. The major factors driving the growth in the flow cytometry market include advancements in technology, increasing adoption of flow cytometry products in clinical diagnostics, rising prevalence of chronic diseases, growing biopharmaceutical R&D, and the need for precision medicine. The significant rise in oncology research has increased the demand for flow cytometry products and services. Additionally, the integration of AI and machine learning is enhancing data analysis capabilities, further fueling market growth. Download PDF Brochure: Browse in-depth TOC on "Epigenetics Market" 365 - Tables45 - Figures353 - Pages By offering, the global epigenetics market is segmented into various categories, including kits and reagents, enzymes, instruments and accessories, software, and services. Within the kits and reagents category, there are sub-segments such as antibodies, chip-sequencing kits and reagents, bisulfite conversion kits and reagents, whole-genome amplification kits and reagents, 5-HMC and 5-MC analysis kits and reagents, histones, as well as other kits and reagents. In 2024, the Antibodies segment is projected to command the largest market share. This is attributed to the increasing reliance on antibodies for the detection, identification, and modification of proteins, along with their essential function in monitoring cellular regulation and gene expression. Consequently, the growth of the antibodies segment is expected to accelerate throughout the forecast period due to these advancements. By Method, the epigenetics market segmentation by methodology includes DNA methylation, histone modifications, and additional approaches such as non-coding RNA interactions and chromatin remodeling. The DNA methylation segment is projected to exhibit a robust compound annual growth rate (CAGR) throughout the forecast period, primarily driven by its proven effectiveness in oncology research applications. By geography, The Asia Pacific region is projected to experience the most rapid growth within the epigenetics market. This expansion is driven by the increasing global footprint of local companies through strategic alliances and collaborations, alongside continuous enhancements in healthcare infrastructure in emerging economies. Moreover, there is a heightened emphasis on advancing capabilities in Next-Generation Sequencing (NGS), which is further propelling market development in the region. Request Sample Pages : Key players in the epigenetics market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher (US), Active Motif, Inc. (US), Bio-Rad Laboratories, Inc. (US), Promega Corporation (US), Revvity (US), QIAGEN (Germany), among others. Illumina Inc (US): In 2024, Illumina, Inc. maintained a preeminent position in the genomics market, capitalizing on a well-established customer base that includes leading pharmaceutical and biotechnology companies, genomic research institutions, and various government laboratories and hospitals. The firm possesses a dominant market share in the next-generation sequencing (NGS) domain, which affords it a competitive edge when exploring adjacent sectors, such as epigenetic sequencing. A notable move in this direction occurred in June 2025, when Illumina announced its acquisition of SomaLogic. This strategic acquisition is poised to bolster Illumina's footprint in the burgeoning epigenetics market and further its multiomics strategy, integrating diverse biological data for enhanced insights into genomics, transcriptomics, proteomics, and epigenomics. Thermofisher Scientific Inc. (US) Thermo Fisher Scientific Inc. (US) stands out as a prominent player in the epigenetics market in 2024, driven by a robust and diversified product portfolio, an extensive global footprint, and a strategic focus on both organic and inorganic growth initiatives. Notably, in July 2025, the company secured US Food and Drug Administration (FDA) approval for the Oncomine Dx Express Test, utilizing the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay designed for companion diagnostics (CDx) in tumor profiling applications. Thermo Fisher demonstrates a strong commitment to research and development, channeling significant resources into innovation to address the dynamic needs of its clientele. Their comprehensive global distribution network enhances accessibility and customer support, facilitating the delivery of advanced and reliable epigenetics solutions. This multifaceted strategic approach solidifies Thermo Fisher's position as a leading provider in the epigenetics landscape. For more information, Inquire Now! Related Reports: Research Antibodies & Reagents Market Genomics Market Next Generation Sequencing Market PCR Technologies Market Digital PCR and qPCR Market Get access to the latest updates on Epigenetics Companies and Epigenetics Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
